# Medicinal plants in the management of muscle loss and sarcopenia: A narrative review of preclinical and clinical evidence from eight species. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-muscle-health-sarcopenia-evidence-review-2024/ > **Published:** 2026-04-27T18:27:43-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:00:47-04:00 > **Clinical Summary:** Narrative review examines cannabis and seven other medicinal plants for muscle health and sarcopenia management. Clinical evidence analysis and limitations. --- CED Clinical Relevance  #70Notable Clinical Interest Evidence Brief | CED ClinicNarrative review identifies Cannabis sativa among eight medicinal plants with potential muscle-preserving properties for sarcopenia management. SarcopeniaMuscle HealthCannabis[Traditional Medicine](https://cedclinic.com/cannabis-insomnia-randomized-trial/)Narrative Review Narrative review identifies Cannabis sativa among eight medicinal plants with potential muscle-preserving properties for sarcopenia management. What This Study Teaches Us This narrative review synthesizes existing evidence suggesting that Cannabis sativa and seven other medicinal plants may offer muscle-preserving properties relevant to sarcopenia management. The review methodology appears to integrate both traditional medicine knowledge from Persian practice with contemporary research across multiple study types. Why This Matters Sarcopenia affects up to 16% of older adults globally and current pharmacological options remain limited. Natural therapies that could support muscle preservation represent an important area of investigation, particularly given the safety profile concerns with existing interventions. Study Snapshot Study Type Narrative Review Population Literature examining effects of eight medicinal plants on muscle health across preclinical and clinical studies Intervention Cannabis sativa, Chrysanthemum morifolium, Crocus sativus, Eriobotrya japonica, Glycine max, Olea europaea, Salvia rosmarinus, and Sesamum indicum Comparator Not applicable for narrative review Primary Outcome Effects on muscle preservation, sarcopenia, and muscle atrophy Key Finding Eight medicinal plants demonstrated potential muscle health benefits across various study designs Journal Phytomedicine Year 2024 Clinical Bottom Line While this narrative review suggests Cannabis sativa may have muscle-preserving properties, the evidence synthesis alone cannot establish clinical efficacy or guide specific therapeutic recommendations. The inclusion of cannabis among traditionally recognized muscle-supporting herbs warrants further investigation through controlled trials. What This Paper Does Not Show As a narrative review, this paper cannot demonstrate causation or provide quantified effect sizes for any of the studied plants. The abstract does not reveal the quality, quantity, or consistency of evidence supporting cannabis specifically for muscle preservation. Where This Paper Deserves Skepticism Narrative reviews are inherently subject to selection bias and lack the systematic methodology of meta-analyses. The criteria for including these eight specific plants and the strength of evidence supporting each remains unclear from the abstract alone. Dr. Caplan's Take I find it intriguing that Cannabis sativa appears alongside well-established botanicals in this muscle health context, but I need to see the actual evidence quality before drawing clinical conclusions. The muscle-wasting pathway involvement of the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) suggests biological plausibility, but narrative reviews can’t substitute for rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). What a Careful Reader Should Take Away This review identifies Cannabis sativa as potentially relevant to muscle preservation research, but readers should recognize that narrative reviews represent hypothesis-generating rather than definitive evidence. The biological rationale for cannabis in muscle health deserves investigation through properly controlled studies. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Medicinal%20plants%20in%20the%20management%20of%20muscle%20loss%20and%20sarcopenia%3A%20A%20narrative%20review%20of%20preclinical%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-muscle-health-sarcopenia-evidence-review-2024%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-muscle-health-sarcopenia-evidence-review-2024%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Medicinal%20plants%20in%20the%20management%20of%20muscle%20loss%20and%20sarcopenia%3A%20A%20narrative%20review%20of%20preclinical%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fcannabis-muscle-health-sarcopenia-evidence-review-2024%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Table of Contents - [FAQ](#FAQ)[Can cannabis help prevent muscle loss in older adults with sarcopenia?](#Can_cannabis_help_prevent_muscle_loss_in_older_adults_with_sarcopenia) - [What is the mechanism by which cannabis might support muscle health?](#What_is_the_mechanism_by_which_cannabis_might_support_muscle_health) - [Is there sufficient clinical evidence to recommend cannabis for muscle wasting conditions?](#Is_there_sufficient_clinical_evidence_to_recommend_cannabis_for_muscle_wasting_conditions) - [How does cannabis compare to other medicinal plants for muscle health?](#How_does_cannabis_compare_to_other_medicinal_plants_for_muscle_health) - [What are the clinical considerations for using cannabis in sarcopenic patients?](#What_are_the_clinical_considerations_for_using_cannabis_in_sarcopenic_patients) - [Related](#Related) ## FAQ #### Can cannabis help prevent muscle loss in older adults with sarcopenia? This narrative review identifies Cannabis sativa as one of eight medicinal plants with potential muscle-preserving properties for sarcopenia management. However, the evidence is primarily preclinical, and more robust [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are needed to establish cannabis’s efficacy and safety for muscle preservation in aging populations. #### What is the mechanism by which cannabis might support muscle health? While the study doesn’t detail specific mechanisms, [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) likely interact with the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), which plays roles in muscle metabolism and inflammation regulation. The anti-inflammatory and metabolic effects of cannabinoids may contribute to muscle preservation, though more research is needed to clarify these pathways. #### Is there sufficient clinical evidence to recommend cannabis for muscle wasting conditions? Currently, the evidence base consists mainly of preclinical studies, with limited clinical trial data specifically for muscle preservation. This narrative review highlights the need for well-designed human studies to validate cannabis’s potential therapeutic role in sarcopenia and muscle wasting disorders. #### How does cannabis compare to other medicinal plants for muscle health? The review examined eight medicinal plants including Cannabis sativa alongside species like Glycine max and Olea europaea, all showing potential muscle-preserving properties. Cannabis was selected based on traditional medicine use and supporting evidence, but direct comparative efficacy data between these plants is limited. #### What are the clinical considerations for using cannabis in sarcopenic patients? Clinicians should consider that sarcopenic patients are often older adults who may be more sensitive to cannabis’s psychoactive effects and [drug interactions](https://cedclinic.com/cannabis-liver-interactions-study-insights/). Given the preliminary nature of the evidence, cannabis should only be considered as part of a comprehensive approach that includes established interventions like resistance training and adequate protein intake. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).